Larimar Therapeutics (LRMR) Capital Expenditures Growth (5y) (2018 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Capital Expenditures Growth (5y) (2018 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 35.69% |
| Mar 31, 2025 | -3.32% |
| Dec 31, 2024 | 56.61% |
| Sep 30, 2024 | 14.87% |
| Jun 30, 2024 | 63.24% |
| Mar 31, 2024 | 11.55% |
| Dec 31, 2023 | 69.52% |
| Sep 30, 2023 | -16.47% |
| Jun 30, 2023 | -13.65% |
| Mar 31, 2023 | -51.57% |
| Mar 31, 2022 | 58.49% |
| Jun 30, 2021 | -16.42% |
| Mar 31, 2021 | -3.72% |
| Dec 31, 2020 | 1.36% |
| Sep 30, 2020 | -41.66% |
| Mar 31, 2020 | 16.52% |
| Dec 31, 2019 | 3.50% |
| Sep 30, 2019 | 0.00% |
| Jun 30, 2019 | 29.67% |
| Mar 31, 2019 | 17.08% |